ABSTRACT
Serine/threonine kinase 4 deficiency (STK4 or MST1, OMIM:614868) is an autosomal recessive (AR) combined immunodeficiency that can present with skin lesions such as epidermodysplasia verruciformis-like lesions (EVLL). Herein, we describe a 17-year-old male patient born from consanguineous parents presenting with recurrent respiratory infections, verruciform plaques, poikiloderma, chronic benign lymphoproliferation, and Sjögren syndrome with suspected interstitial lymphocytic pneumonia.
Subject(s)
Epidermodysplasia Verruciformis , Primary Immunodeficiency Diseases , Skin Diseases , Male , Humans , Adolescent , Epidermodysplasia Verruciformis/diagnosis , Epidermodysplasia Verruciformis/genetics , Epidermodysplasia Verruciformis/pathology , Papillomaviridae , Primary Immunodeficiency Diseases/diagnosis , Protein Serine-Threonine Kinases , Intracellular Signaling Peptides and ProteinsABSTRACT
PURPOSE: Persistent human papillomavirus infection (PHPVI) causes cutaneous, anogenital, and mucosal warts. Cutaneous warts include common warts, Treeman syndrome, and epidermodysplasia verruciformis, among others. Although more reports of monogenic predisposition to PHPVI have been published with the development of genomic technologies, genetic testing is rarely incorporated into clinical assessments. To encourage broader molecular testing, we compiled a list of the various monogenic etiologies of PHPVI. METHODS: We conducted a systematic literature review to determine the genetic, immunological, and clinical characteristics of patients with PHPVI. RESULTS: The inclusion criteria were met by 261 of 40,687 articles. In 842 patients, 83 PHPVI-associated genes were identified, including 42, 6, and 35 genes with strong, moderate, and weak evidence for causality, respectively. Autosomal recessive inheritance predominated (69%). PHPVI onset age was 10.8 ± 8.6 years, with an interquartile range of 5 to 14 years. GATA2,IL2RG,DOCK8, CXCR4, TMC6, TMC8, and CIB1 are the most frequently reported PHPVI-associated genes with strong causality. Most genes (74 out of 83) belong to a catalog of 485 inborn errors of immunity-related genes, and 40 genes (54%) are represented in the nonsyndromic and syndromic combined immunodeficiency categories. CONCLUSION: PHPVI has at least 83 monogenic etiologies and a genetic diagnosis is essential for effective management.
Subject(s)
Epidermodysplasia Verruciformis , Papillomavirus Infections , Warts , Humans , Child, Preschool , Child , Adolescent , Papillomavirus Infections/complications , Papillomavirus Infections/genetics , Warts/genetics , Warts/complications , Epidermodysplasia Verruciformis/genetics , Epidermodysplasia Verruciformis/complications , Skin , Syndrome , Membrane Proteins/genetics , Guanine Nucleotide Exchange FactorsABSTRACT
Epidermodysplasia verruciformis (EV) is a rare genodermatosis associated with susceptibility to beta-human papilloma virus (HPV) infection. EV patients develop disseminated warts and non-melanoma skin cancer, mainly squamous cell carcinomas (SCC) that are locally aggressive. EV pathogenesis is not yet fully understood, but alterations in the p16 gene play a role in the pathogenesis of neoplasms caused by high-risk genital HPV. To explore its role in EV lesions, we compared p16 expression in SCC from patients with and without EV. Tissue microarray slides composed of 27 SCC from EV patients, and 35 from non-EV patients were stained with an anti-p16 antibody. Twenty (74%) EV tumors exhibited diffuse (nuclear and cytoplasmic) p16 expression, one (4%) displayed focal expression, and six (22%) displayed no p16 staining. Eleven (31%) SCC from non-EV patients presented diffuse p16 staining, 14 (40%) displayed focal expression and 10 (29%) did not express p16. The frequency of diffuse p16 expression was higher in EV tumors than in SCC from patients without EV. The frequency of diffuse p16 expression in moderately and poorly differentiated EV-SCC was similarly higher than non-EV tumors with the same degree of differentiation. The diffuse expression of p16 in EV-SCC suggests that changes in the p16 gene, probably resulting in a functionally defective protein, may be one factor determining the locally aggressive clinical behavior of SCC in young EV patients.
Subject(s)
Carcinoma, Squamous Cell/pathology , Cyclin-Dependent Kinase Inhibitor p16/metabolism , Epidermodysplasia Verruciformis/pathology , Papillomavirus Infections/pathology , Skin Neoplasms/pathology , Adult , Age Factors , Aged , Biopsy , Carcinoma, Squamous Cell/immunology , Carcinoma, Squamous Cell/virology , Disease Susceptibility/immunology , Epidermodysplasia Verruciformis/genetics , Epidermodysplasia Verruciformis/immunology , Female , Humans , Immunohistochemistry , Male , Papillomaviridae/isolation & purification , Papillomavirus Infections/immunology , Papillomavirus Infections/virology , Rare Diseases/genetics , Rare Diseases/immunology , Rare Diseases/pathology , Skin/pathology , Skin/virology , Skin Diseases, Genetic/genetics , Skin Diseases, Genetic/immunology , Skin Diseases, Genetic/pathology , Skin Neoplasms/immunology , Skin Neoplasms/virology , Tissue Array AnalysisABSTRACT
BACKGROUND: The presence of arginine at codon 72 in p53 protein is proposed to be a genetic risk factor in human papillomavirus (HPV)-related carcinogenesis. OBJECTIVE: To study the prevalence of p53 polymorphism at codon 72 in skin biopsies of epidermodysplasia verruciformis (EV) patients compared to DNA samples from healthy individuals. PATIENTS AND METHODS: DNA samples extracted from normal skin and tumor biopsies of 22 Brazilian patients with EV and blood samples from 27 healthy Brazilian individuals were studied for p53 codon 72 polymorphisms using restriction fragment length polymorphism (RFLP) analysis. RESULTS: All EV patients with the malignant form of EV were homozygous for arginine (Arg/Arg) at codon 72 of the p53 gene, in contrast to none with the benign form (P < 0.0001). CONCLUSIONS: p53 arginine polymorphism is likely to be associated with the development of skin malignancies in EV patients from Brazil.
Subject(s)
Cell Transformation, Neoplastic/genetics , Epidermodysplasia Verruciformis/genetics , Papillomavirus Infections/complications , Skin Neoplasms/genetics , Tumor Suppressor Protein p53/genetics , Arginine/genetics , Brazil , Epidermodysplasia Verruciformis/complications , Genetic Predisposition to Disease/genetics , Humans , Polymorphism, Genetic/genetics , Prevalence , Risk FactorsABSTRACT
BACKGROUND: Epidermodysplasia verruciformis (EV) is a rare genetic disorder characterized by development of lesions associated with human papillomavirus in early childhood and malignant transformation in approximately half of individuals during adulthood. The persistence of human papillomavirus infection in EV is thought to be a result of an immunogenetic defect, which determines the generation of several cytokines capable of down-regulating cell-mediated immunity. OBJECTIVE: We sought to study the prevalence of interleukin 10 (IL-10) promoter polymorphisms in skin biopsy specimens of patients with EV compared with DNA samples from healthy individuals. Patients and methods DNA samples extracted from normal skin of 22 patients from Brazil with EV and blood samples from 27 healthy Brazilian individuals were studied for IL-10 promoter polymorphisms using restriction fragment length polymorphism analysis. RESULTS: The patients with EV showed an increased rate of low-production genotypes of IL-10 compared with control subjects (P =.003). Patients with EV and skin cancer were more likely to have low-production IL-10 genotypes than patients with benign forms of EV. CONCLUSION: IL-10 genotypes associated with low levels of IL-10 production may have an important role in the pathogenesis of EV, including the susceptibility for development of skin cancer in patients with EV.
Subject(s)
Epidermodysplasia Verruciformis/genetics , Interleukin-10/genetics , Polymorphism, Single Nucleotide , Brazil , Genetic Predisposition to Disease , Genotype , Haplotypes , Humans , Polymorphism, Genetic , Promoter Regions, Genetic/genetics , Seroepidemiologic StudiesABSTRACT
Epidermodysplasia verruciformis is a rare genodermatosis associated with a high risk of skin cancer. This condition is characterized by an abnormal susceptibility to specific related human papillomavirus genotypes, including the oncogenic HPV5. Epidermodysplasia verruciformis is usually considered as an autosomal recessive disease. We recently mapped a susceptibility locus for epidermodysplasia verruciformis (EV1) to chromosome 17qter within the 1 cM interval between markers D17S939 and D17S802. We report here the genotyping for 10 microsatellite markers spanning 29 cM around EV1 in two consanguineous epidermodysplasia verruciformis families from Colombia (C2) and France (F1) comprising five patients and two patients, respectively. Using homozygosity mapping, linkage with 17qter markers was observed for family C2 only. Multipoint linkage analysis yielded maximum multipoint LOD-score values above 10 between markers D17S1839 and D17S802 encompassing the EV1 locus. A genome-wide search performed in family F1 yielded evidence for linkage between epidermodysplasia verruciformis and the chromosomal 2p marker D2S365. Nine additional microsatellite markers spanning 15 cM in this region were analyzed. Assuming an autosomal recessive inheritance with a complete penetrance, the expected maximum two-point LOD-score value of 1.8 was obtained for three markers and multipoint linkage analysis yielded a maximum LOD-score value of 3. 51 between markers D2S2144 and D2S392. Haplotype analysis allowed to map a candidate region for a second epidermodysplasia verruciformis susceptibility locus (EV2) within the 8 cM interval between markers D2S171 and D2S2347 of the 2p21-p24 region. In contrast, linkage with 2p markers was excluded for family C2 and for the three families in which we mapped EV1 previously. The disclosure of two susceptibility loci for epidermodysplasia verruciformis provides evidence for a nonallelic heterogeneity in this disease.
Subject(s)
Chromosomes, Human, Pair 17 , Chromosomes, Human, Pair 2 , Epidermodysplasia Verruciformis/genetics , Adolescent , Adult , Child , Chromosome Mapping , Colombia , Family Health , Female , France , Genetic Heterogeneity , Genetic Predisposition to Disease , Humans , Male , PedigreeABSTRACT
FUNDAMENTOS - A epidermodisplasia verruciforme é causada pelo HPV, apresentando alta incidência familiar, concomitância de distúbios imunológicos e possibilidade de transformaçäo carcinomatosa. OBJETIVOS - Foi revista a literatura sobre os HPV, com ênfase para epidermodisplasia verruciforme, correlacionando-a com a nossa casuística na tentativa de contribuir para melhor conhecimento da enfermidade. MÉTODO - Estudaram-se oito pacientes com epidermodisplasia verruciforme por meio de anamnese, observaçäo clínica, exames laboratoriais, genética, histopatologia, imunologia e tratamento. Foram analisados histopatologicamente dois casos de verugas planas, e comparados com a epidermodisplasia verruciforme. RESULTADOS - Os pacientes apresentaram quadro clínico-histopatológico peculiar aos encontrados na epidermodisplasia verruciforme pelo grupo HPV-5 e similares, com nítido acometimento familiar, alteraçoes imunológicas, evoluçäo crônica e resistência às terapêuticas administradas. CONCLUSOES - 1. A epidermodisplasia verruciforme apresentou expressöes clínicas polimorfas, com evoluçäo crônica e progressiva. As lesöes eram geralmente assintomáticas, com distribuiçäo disseminada e simétrica. A área mais acometida foi a face, com palmas, plantas, mucosas e couro cabeludo poupados; 2. Em todos os pacientes estudados, a ezpressäo clínica da doença era distinta da apresentaçäo clínica encontrada em casos de verrugas planas, sendo histologicamente típica de epidermodisplasia verruciforme (grupo HPV5-símile); 3. Foram observadas nos pacientes alteraçoes imunitárias humorais e celulares; e 4. A resistência às terapêuticas foi marcante. Apenas com o uso do etretinato, houve regressäo parcial das lesöes